{"id":915428,"date":"2025-12-02T16:21:43","date_gmt":"2025-12-02T21:21:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/"},"modified":"2025-12-02T16:21:43","modified_gmt":"2025-12-02T21:21:43","slug":"black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/","title":{"rendered":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update"},"content":{"rendered":"
\n

\n Webcast to be held Wednesday, December 3, at 8:00am ET<\/em>\n <\/p>\n

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.<\/p>\n

\n Webcast information<\/strong>\n <\/p>\n

The webcast can be accessed under \u201cEvents and Presentations\u201d on the Investors section of the Black Diamond website at\u00a0www.blackdiamondtherapeutics.com<\/u><\/a>. A replay of the webcast will be available following the completion of the event.<\/p>\n

\n About Black Diamond Therapeutics<\/strong>\n <\/p>\n

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company\u2019s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit\u00a0www.blackdiamondtherapeutics.com<\/u><\/a>.<\/p>\n

From time to time, we may use our website or our LinkedIn profile at www.linkedin.com\/company\/black-diamond-therapeutics<\/u><\/a> to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com<\/a><\/u>. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.<\/p>\n

\n Contact<\/strong>\n <\/p>\n

For Investors:
investors@bdtx.com<\/u><\/a><\/p>\n

For Media:
media@bdtx.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d on the Investors section of the Black Diamond website at\u00a0www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event. About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that … <\/p>\n

Continue reading “Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBlack Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d on the Investors section of the Black Diamond website at\u00a0www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event. About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that … Continue reading "Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T21:21:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update\",\"datePublished\":\"2025-12-02T21:21:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/\",\"name\":\"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=\",\"datePublished\":\"2025-12-02T21:21:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/","og_locale":"en_US","og_type":"article","og_title":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk","og_description":"Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d on the Investors section of the Black Diamond website at\u00a0www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event. About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that … Continue reading \"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T21:21:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update","datePublished":"2025-12-02T21:21:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/","name":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=","datePublished":"2025-12-02T21:21:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDQyNSM3Mjk5MDUwIzIxOTAwNTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}